284 related articles for article (PubMed ID: 30081149)
41. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
[TBL] [Abstract][Full Text] [Related]
42. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
[TBL] [Abstract][Full Text] [Related]
43. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
Chan CS; Laddha SV; Lewis PW; Koletsky MS; Robzyk K; Da Silva E; Torres PJ; Untch BR; Li J; Bose P; Chan TA; Klimstra DS; Allis CD; Tang LH
Nat Commun; 2018 Oct; 9(1):4158. PubMed ID: 30315258
[TBL] [Abstract][Full Text] [Related]
44. Impact of DAXX and ATRX expression on telomere length and prognosis of breast cancer patients.
Hussien MT; Shaban S; Temerik DF; Helal SR; Mosad E; Elgammal S; Mostafa A; Hassan E; Ibrahim A
J Egypt Natl Canc Inst; 2020 Aug; 32(1):34. PubMed ID: 32856116
[TBL] [Abstract][Full Text] [Related]
45. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
47. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
[TBL] [Abstract][Full Text] [Related]
48. Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer.
Buentzel J; Yao S; Elakad O; Lois AM; Brünies J; König J; Hinterthaner M; Danner BC; Ströbel P; Emmert A; Bohnenberger H
Medicine (Baltimore); 2019 Aug; 98(31):e16712. PubMed ID: 31374064
[TBL] [Abstract][Full Text] [Related]
49. Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors.
Sato S; Tsuchikawa T; Nakamura T; Sato N; Tamoto E; Okamura K; Shichinohe T; Hirano S
Oncol Rep; 2014 Dec; 32(6):2753-9. PubMed ID: 25310565
[TBL] [Abstract][Full Text] [Related]
50. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
51.
Baek J; Jang NR; Shim YR; Gu MJ
Indian J Pathol Microbiol; 2022; 65(3):598-603. PubMed ID: 35900487
[TBL] [Abstract][Full Text] [Related]
52. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
53. ATRX and DAXX: Mechanisms and Mutations.
Dyer MA; Qadeer ZA; Valle-Garcia D; Bernstein E
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28062559
[TBL] [Abstract][Full Text] [Related]
54. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
[TBL] [Abstract][Full Text] [Related]
56. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
[TBL] [Abstract][Full Text] [Related]
57. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
Mäkinen N; Aavikko M; Heikkinen T; Taipale M; Taipale J; Koivisto-Korander R; Bützow R; Vahteristo P
PLoS Genet; 2016 Feb; 12(2):e1005850. PubMed ID: 26891131
[TBL] [Abstract][Full Text] [Related]
58. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
59. CD47 expression and CD163
Imam R; Chang Q; Black M; Yu C; Cao W
BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
[TBL] [Abstract][Full Text] [Related]
60. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
